Randomised controlled trial
Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial
- Randomised controlled trial
- international
- adaptive
- platform trial
- open-label
- 1:1
Authors' conclusion
Crizanlizumab, a P-selectin inhibitor, did not result in improvement in organ support-free days in patients hospitalized with COVID-19.
Study context
- Population
- Patients hospitalized with COVID-19 with moderate or severe illness421 with known 21-day outcomes
- Participants
- 422 patients
- Comparison
- Crizanlizumab plus standard of care vs standard of care alone
- Primary endpoint
- Organ support-free days (ordinal scale of days alive free of organ support)
- Follow-up
- First 21 days after trial entry
Primary result
Organ support-free days · 21 days
Adjusted odds ratio
0.70
95% CI 0.43–1.16
Events by treatment group
Crizanlizumab vs Standard of care
adjusted OR 0.70 (95% CI 0.43–1.16)
As reported in the abstract
Further findings
| Outcome | Crizanlizumab | Standard of care | HR (95% CrI) | |
|---|---|---|---|---|
| Death · CrI; probability of HR>1 = 0.879 · CrI | 17.5% | 12.8% | 1.33 (0.85–2.21) | |
| 0.512Hazard ratio (log scale) |
Original publication
Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial. Circulation. Published 25 June 2023. doi:10.1161/circulationaha.123.065190
Summarised from the published abstract; every number is checked against it